Scalable
Driven by Data
Secure
Personalized
Proven
Trusted by Trial Leaders
Seamless Setup in 3 Month
Scalable
Driven by Data
Secure
Personalized
Proven
Trusted by Trial Leaders
Seamless Setup in 3 Month
Scalable
Driven by Data
Secure
Personalized
Proven
Trusted by Trial Leaders
Seamless Setup in 3 Month
Scalable
Driven by Data
Secure
Personalized
Proven
Trusted by Trial Leaders
Seamless Setup in 3 Month
Scalable
Driven by Data
Secure
Personalized
Proven
Trusted by Trial Leaders
Seamless Setup in 3 Month

PHARMA FACES PERSISTENT CHALLENGES IN RESPIRATORY CLINICAL TRIALS WITH SPIROMETRY ENDPOINTS

Data variability
Patient recruitment
Operational inefficiencies

9 out of 10 trials require onsite (at clinic) spirometry

 In-person spirometry measurements result in a 30% intra-individual variability, increasing trial time, cost, and data requirements. 9 out of 10 trials require onsite (at clinic) spirometry causing logistic and scheduling conflicts exacerbating data collection- increased cost, inconvenience, more participants, and more visits to meet the statistical requirements- 

Why Traditional Spirometry Fails

One data point per visit

The COPD patient population is underserved both for diagnosis and monitoring.

Limited access

patient must wait for appointment, drive to clinic, limited access to Respiratory Therapists (SME)

Higher Variability

up to 40% variability noted between visits

SCALABLE PLATFORM FOR REAL-TIME, HIGH-QUALITY, REMOTE SPIROMETRY

Although traditional, in-person spirometry is the gold standard, it is burdensome to patients and relies heavily on technician skill. Infrequent, in-person spirometry measurements result in a 30% intra-individual variability, increasing trial time, cost, and data requirements.

REMOTE SPIROMETRY, GUIDED BY CREDENTIALED RESPIRATORY THERAPISTS PRODUCES RELIABLE DATA SETS

ATS/ERS

The skill gap of staff performing spirometry in clinical trials reduces adherence to global quality standards (ATS/ERS)

40%

Real time Respiratory Therapists coaching reduces variability by up to 40% through the PulManage platform

More Data

Spirometry collection in the home generates more frequent and consistent data than on site 

PulManage Data is Rich

Not Just Spirometry Data

Also, real-world data from wearables and PROs

We can contextualize the spirometry data which makes it more impactful and acomplete picture of the patient journey

Our Mission

To make respiratory clinical trials faster, smarter, and more accessible through innovative technology, patient-first design, and clinical-grade data collection at scale.

Serving All Trial Phases and Real World Studies

Patient Benefits:

  • Improves access, convenience, & experience
  • Enables real-time monitoring with personalized support and insights

sponsor benefits

  • Richer data
  • Reduces variability
  • Cleaner trial outcomes
  • Scalable data integration API

Trial logistics

  • Accelerates timelines
  • Broader patient access
  • Supports smaller, more efficient studies
  • Scales with trial growth

Explore Our Satisfied Client Testimonial

In the SEAS study, we found it feasible to remotely capture both physiological data (spirometry) and patient-reported outcomes in a single platform, expanding our ability to conduct COPD research in rural settings

Dr. Sarah Miller

SEAS- Remote Spirometry, Education, and Action for COPD

At AlphaNet, we have over 7,500 persons in Canada and the US who are diagnosed with alpha-1 antitrypsin deficiency participating in our disease management program--our Subscribers. We are excited to use PulManage with wearables to gather data, investigate approaches, and explore opportunities to improve health and quality of life for our subscribers

Mark Delvaux

Mark Delvaux, CEO AlphaNet; Exacerbation prevention in alpha-1 antitrypsin deficiency (AATD)

Building on lessons learned in SEAS, we will leverage PulManage to capture remote spirometry and PROs in a large-scale clinical trial. This will allow us to evaluate functional outcomes and patient experiences concurrently in a flexible and adaptive trial design.

Dr. Sarah Miller

D r. Sarah Miller; RESPfit- Respiratory Muscle FITness Training in COPD

In the SEAS study, we found it feasible to remotely capture both physiological data (spirometry) and patient-reported outcomes in a single platform, expanding our ability to conduct COPD research in rural settings

Dr. Sarah Miller

SEAS- Remote Spirometry, Education, and Action for COPD

Building on lessons learned in SEAS, we will leverage PulManage to capture remote spirometry and PROs in a large-scale clinical trial. This will allow us to evaluate functional outcomes and patient experiences concurrently in a flexible and adaptive trial design.

Dr. Sarah Miller

D r. Sarah Miller; RESPfit- Respiratory Muscle FITness Training in COPD